A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
Status:
Completed
Trial end date:
2017-03-03
Target enrollment:
Participant gender:
Summary
This two-part study will evaluate how safe LY3154207 is and the effects it has on the body.
Part A will include healthy participants. Each participant will receive daily doses of
LY3154207 or placebo for 14 days. Part A will last approximately 4 weeks including a 17 day
stay in the clinical research unit (CRU) and follow-up.
Part B is contingent on the results of Part A. Part B will include participants with
Parkinson's disease. Each participant will receive daily doses of LY3154207 or placebo for 14
days. Part B will last approximately 4 weeks including a 17 day stay in the CRU and
follow-up.
Both Part A and Part B will require screening within 30 days prior to the start of the study.